Beam Therapeutics, Inc. (BEAM)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$25.87-6.91%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · BEAM
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 47.6% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| -61.2% |
Growth built into the price is above our model estimate.
The price assumes 108.7 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name has been missing across recent quarters and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 65 industry peers · Company calendar date is not available
BEAM — earnings miss
Dated 2026-11-03
as well as in the accompanying Exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company, under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Why it matters: The first patient data will test whether this program can move beyond early trial work.
Supportive ifBeam reports initial Phase 1/2 patient data in 2026, with a clear safety readout and signs of benefit.
Worry ifBeam reports a serious safety concern or no sign of benefit. Or it reports no early data by December 31, 2026.
Why it matters: The first patient dosing would test the move from IND clearance to human trials.
Supportive ifBeam starts the Phase 1/2 trial and doses a patient with the R408W mutation by year-end 2026.
Worry ifThe trial has not started or no patient has been dosed by December 31, 2026, or a safety issue delays the start.
Why it matters: Updated trial data and a BLA filing are key steps toward a possible SCD launch.
Supportive ifBy December 31, 2026, Beam reports new BEACON data and submits the risto-cel BLA.
Worry ifThe data report or BLA filing slips past year-end, or Beam reports a safety issue that delays filing.
Why it matters: Beam has no product sales in the provided results, so its cash helps fund several trials and filings.
Worry ifBeam confirms cash and planned credit draws still fund operations into mid-2029.
Less concerning ifBeam lowers its runway outlook to before mid-2029 or says the planned $200 million credit draw is not available.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$237 on $10,000 · ±2.4% | How much price usually moves either way. |
| Bad day | $664 loss on $10,000 · 6.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,908 loss on $10,000 · 39.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The data and enrollment pace test whether BEAM-302 can support the planned AATD approval path.
Supportive ifAt ERS, new data show good safety and AAT gains. The pivotal cohort enrolls about 50 patients on plan.
Worry ifThe data show serious safety concerns or a weak AAT response. Or enrollment falls well behind the planned cohort of about 50 patients.